Loading…
Phi Sciences received an FDA Warning Letter on January 30, 2019, regarding drug products, though the specific violations cannot be detailed due to unavailable letter content and subject line information. Based on the limited metadata, this warning was issued by the FDA's drug regulatory authority, indicating the company had compliance concerns with pharmaceutical manufacturing, marketing, or quality standards. Without access to the complete warning letter text, the precise nature and scope of the violations remain unclear. This letter represents a formal FDA enforcement action requiring the company to take corrective measures to achieve compliance.